Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses Resolver to COR Therapeutics

NEW YORK, Nov. 26 - Rosetta Biosoftware announced on Monday that it has licensed its Resolver gene-expression data-analysis system to COR Therapeutics.


Rosetta's technology will "help us lay the groundwork for the development of novel pharmaceutical products to treat cardiovascular diseases," said James N. Topper, vice president for biology at South San Francisco, Calif.-based COR Therapeutics.


Financial terms of the agreement were not disclosed.


The Resolver bioinformatics system is distributed by Rosetta, the Kirkland, Wash.-based Merck business, and Palo Alto, Calif.-based Agilent Technologies.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.